News articles about Axovant Sciences (NYSE:AXON) have trended somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Axovant Sciences earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.3854141539996 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Axovant Sciences Ltd (AXON) Downgraded by BidaskClub (americanbankingnews.com)
- Axovant Sciences: The Progressively Contentious Alzheimer’s Claim (seekingalpha.com)
- Axovant Sciences’ (AXON) Sell Rating Reiterated at Chardan Capital (americanbankingnews.com)
- Axovant Sciences Ltd. (AXON) has a value of $19.91 per share While MacroGenics, Inc. (MGNX) is stand at $17.16 – Stocks Gallery (stocksgallery.com)
- Axovant Sciences Joins Elite Club Of Stocks With RS Ratings Over 90 (finance.yahoo.com)
A number of brokerages have recently issued reports on AXON. BidaskClub lowered Axovant Sciences from a “sell” rating to a “strong sell” rating in a research note on Friday. Chardan Capital reaffirmed a “sell” rating and issued a $8.00 price target on shares of Axovant Sciences in a research note on Thursday. Evercore ISI began coverage on Axovant Sciences in a research note on Friday, September 8th. They issued an “outperform” rating and a $30.00 price target on the stock. Jefferies Group LLC set a $40.00 price target on Axovant Sciences and gave the stock a “buy” rating in a research note on Friday, August 25th. Finally, Zacks Investment Research lowered Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Four investment analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $26.05.
Axovant Sciences (NYSE:AXON) opened at 21.34 on Friday. The firm’s market cap is $2.29 billion. Axovant Sciences has a 1-year low of $11.01 and a 1-year high of $21.85. The firm’s 50-day moving average price is $20.44 and its 200-day moving average price is $17.12.
Axovant Sciences (NYSE:AXON) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12). On average, equities research analysts anticipate that Axovant Sciences will post ($2.36) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Axovant Sciences (AXON) Earning Somewhat Positive News Coverage, Report Shows” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://transcriptdaily.com/2017/09/17/axovant-sciences-axon-earning-somewhat-positive-news-coverage-report-shows.html.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.